Abstract
Pulmonary metastasectomy (PM) with curative intent is a routinely performed surgical procedure in a variety of end-stage malignant diseases with secondary spreading to the lungs. Current selection criteria for PM are solely based on few clinical factors without regarding the biology and behavior of the underlying malignant disease. Hence, great variation in outcome and recurrence patterns after PM is reported in the literature. In a variety of therapeutic options, prognostic and predictive biomarkers have become an integral part in planning targeted therapies. However, data on biomarkers in PM is sparse. This review summarizes recently reported tissue-based and circulating molecular markers in patients receiving PM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
